Cancer Biologics Market to grow with a CAGR of 7.17%
Increasing healthcare infrastructure and
a supportive regulatory environment are the major drivers for the Global Cancer
Biologics Market.
According to TechSci Research report, “Global
Cancer Biologics Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Cancer Biologics Market has
valued at USD 94.10 billion in 2022 and is anticipated to witness an impressive
growth in the forecast period with a CAGR of 7.17% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market. Targeted therapies are a significant driver of demand in the Global
Cancer Biologics Market. Targeted therapies, a subset of cancer biologics, are
designed to specifically interfere with the molecular and genetic pathways that
drive cancer growth and progression. They are highly effective in treating
various cancer types, and their specificity makes them a preferred choice for
many patients. Targeted
therapies are at the forefront of the precision medicine revolution in
oncology. By identifying specific genetic mutations, protein markers, or other
biomarkers in a patient's tumor, oncologists can select the most appropriate
targeted therapy. This personalized approach often results in more effective
treatment and fewer side effects. Targeted therapies can be highly effective in blocking the
signals that promote cancer growth. This leads to a higher response rate,
increased progression-free survival, and improved overall survival for many
patients. Unlike
traditional chemotherapy, which can affect both cancer and healthy cells,
targeted therapies are more selective. They primarily target cancer cells,
which reduces the severity and frequency of side effects, leading to a better
quality of life for patients. Ongoing research and development efforts continually
identify new therapeutic targets for cancer treatment. The discovery of novel
targets drives the development of new targeted therapies, expanding the range
of available treatment options.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cancer Biologics Market.”
Oncolytic viruses and next-generation
sequencing (NGS) technologies have significantly improved our comprehension of
the genetic underpinnings of cancer and facilitated the adoption of
personalized medicine strategies. Liquid biopsies offer a less intrusive
substitute for conventional tissue biopsies, serving to monitor treatment
efficacy, identify minimal residual disease, and pinpoint mechanisms of resistance.
In January 2020, Roche has submitted a supplemental biologics license
application (sBLA) to the US Food and Drug Administration (FDA) for the use of
Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the
treatment of unresectable hepatocellular carcinoma (HCC), a type of liver
cancer. This application aims to gain approval for utilizing the combination in
patients who have not previously received systemic therapy. Tecentriq is a
monoclonal antibody that targets PD-L1, and Avastin is a biologic antibody that
acts on the vascular endothelial growth factor (VEGF) protein. By combining
these two drugs, the goal is to enhance the immune system's efficacy in
combating cancer. Resistance and response
variability are significant challenges in the Global Cancer Biologics Market.
These challenges have wide-ranging implications for the development, clinical
use, and effectiveness of cancer biologics. Some cancer patients exhibit innate
resistance, meaning that their cancer cells are inherently less responsive to
treatment. Acquired resistance can develop over time, making initially
effective treatments less so. Tumors are often genetically heterogeneous,
meaning that different parts of the tumor may have distinct genetic profiles.
This can result in variable responses to treatment, with some regions of the
tumor being resistant. Patients may respond differently to cancer
biologics due to factors such as genetics, overall health, and the presence of
other medical conditions. Response can vary widely among individuals. Cancer
cells have the capacity to adapt to treatment over time, developing mechanisms
that enable them to evade the effects of the biologic therapy. This can result
in treatment failure and disease progression. Identifying the right patients
for specific biologics based on predictive biomarkers is a complex process.
Inadequate patient stratification can lead to non-responders and treatment
inefficiency.
Global Cancer Biologics
Market is segmented based on Products, Application, End User, and by region.
Based on the Product, Global Cancer Biologics
Market is segmented into Monoclonal Antibodies, Cytokine-Based
Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint
Inhibitors. Cytokine-based
immunotherapy is a type of cancer treatment that harnesses the power of
cytokines, which are small signaling proteins produced by immune cells, to
stimulate or modulate the immune system's response against cancer. Cytokines
play a critical role in regulating immune cell activity and communication. When
used as cancer therapy, they aim to enhance the immune response, promoting the
body's ability to identify and destroy cancer cells. Two key cytokines used in
this type of immunotherapy are Interferons and Interleukins. Interferons are
proteins produced by immune cells in response to infections or tumors. There
are three main types: alpha, beta, and gamma interferons. Interferon-based
immunotherapy often involves the use of interferon-alpha, which is used to
treat certain types of cancer, such as melanoma, renal cell carcinoma, and some
leukemias. Based on Region, North America held the largest share
in the Global Cancer Biologics Market. The United States and Canada are home to
a significant number of pharmaceutical companies with extensive experience in
biologics development. These companies have the resources and expertise to
bring new biologics to market. In North America, many patients have access to
health insurance that covers the cost of expensive cancer biologics. This
encourages the use of these therapies. The region has strong healthcare education
and public awareness programs that help in early cancer detection and the
understanding of biologic treatment options. North America has a relatively
high per capita income, which can support the affordability of biologics. The
region fosters collaboration between academic institutions, industry, and
healthcare providers, leading to advancements in cancer biologics.
Some of the major companies operating in
the Global Cancer Biologics Market include:
- Roche Holding AG
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Amgen Inc.
- Johnson & Johnson
- Pfizer Inc.
- AstraZeneca plc
- Eli Lilly and Company
- AbbVie Inc.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
for Cancer Biologics. The growth in the competitive landscape and the presence
of well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Cancer Biologics Market in the forecast period," said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
Global management consulting firm.
Cancer Biologics Market by Product (Monoclonal Antibodies,
Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune
Checkpoint Inhibitors), By Application (Non-small Cell Lung Cancer, Prostate
Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others), by End User (Hospitals
& Clinics, Ambulatory Care Centers, Others),), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global
Cancer Biologics Market and provides statistics & information on market
size, structure, and future market growth. The report intends to provide innovative
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Cancer Biologics
Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com